Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001241588 | SCV001414616 | uncertain significance | Hyper-IgM syndrome type 2 | 2019-11-04 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with AICDA-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces threonine with serine at codon 110 of the AICDA protein (p.Thr110Ser). The threonine residue is moderately conserved and there is a small physicochemical difference between threonine and serine. |